Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 3, Pages e1088631
Publisher
Informa UK Limited
Online
2015-09-02
DOI
10.1080/2162402x.2015.1088631
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study).
- (2017) M. Tschaika et al. JOURNAL OF CLINICAL ONCOLOGY
- IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.
- (2017) Marina Tschaika et al. JOURNAL OF CLINICAL ONCOLOGY
- Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation
- (2015) Melanie R. Rutkowski et al. CANCER CELL
- Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
- (2015) Emily Chan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial
- (2015) Renata Ursu et al. CANCER SCIENCE
- Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer
- (2015) Tom J.H. Arends et al. Clinical Genitourinary Cancer
- MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
- (2015) Burghardt Wittig et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Autophagy in malignant transformation and cancer progression
- (2015) L. Galluzzi et al. EMBO JOURNAL
- Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
- (2015) Martin R. Weihrauch et al. EUROPEAN JOURNAL OF CANCER
- MD-2 is required for disulfide HMGB1–dependent TLR4 signaling
- (2015) Huan Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9
- (2015) Umeharu Ohto et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs
- (2015) Rachid Ammi et al. PHARMACOLOGY & THERAPEUTICS
- Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
- (2015) S. Liu et al. SCIENCE
- Toll-like receptor 4 senses oxidative stress mediated by the oxidation of phospholipids in extracellular vesicles
- (2015) Mateja Manček-Keber et al. Science Signaling
- Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders
- (2015) Stefano G. Daniele et al. Science Signaling
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- (2015) Ramy Ibrahim et al. SEMINARS IN ONCOLOGY
- Toll-like receptor 4 senses oxidative stress mediated by the oxidation of phospholipids in extracellular vesicles
- (2015) Mateja Manček-Keber et al. Science Signaling
- Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders
- (2015) Stefano G. Daniele et al. Science Signaling
- Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
- (2015) Jitka Fucikova et al. Frontiers in Immunology
- 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer
- (2015) Jong-Wei Hsu et al. Oncotarget
- Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells
- (2015) Juping Wang et al. Oncotarget
- Targeting Aerobic Glycolysis and HIF-1α Expression Enhance Imiquimod-induced Apoptosis in Cancer Cells
- (2015) Shi-Wei Huang et al. Oncotarget
- Immunogenic cell death inducers as anticancer agents
- (2015) Oliver Kepp et al. Oncotarget
- Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
- (2015) Bojidar M. Kojouharov et al. Oncotarget
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
- (2014) David A. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9
- (2014) Yuyi Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer
- (2014) S. Chatterjee et al. CANCER RESEARCH
- TLR Signals Induce Phagosomal MHC-I Delivery from the Endosomal Recycling Compartment to Allow Cross-Presentation
- (2014) Priyanka Nair-Gupta et al. CELL
- Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
- (2014) L Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
- (2014) Aaron P. Rapoport et al. CLINICAL CANCER RESEARCH
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- The Histidine Transporter SLC15A4 Coordinates mTOR-Dependent Inflammatory Responses and Pathogenic Antibody Production
- (2014) Toshihiko Kobayashi et al. IMMUNITY
- Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells
- (2014) Yuliya Skabytska et al. IMMUNITY
- Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
- (2014) A. Ruzsa et al. INVESTIGATIONAL NEW DRUGS
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2014) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- B lymphocytes undergo TLR2-dependent apoptosis uponShigellainfection
- (2014) Katharina Nothelfer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rapid fucosylation of intestinal epithelium sustains host–commensal symbiosis in sickness
- (2014) Joseph M. Pickard et al. NATURE
- Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
- (2014) Tobias Bald et al. NATURE
- A cell-intrinsic role for TLR2–MYD88 in intestinal and breast epithelia and oncogenesis
- (2014) Ferenc A. Scheeren et al. NATURE CELL BIOLOGY
- TLR7 induces anergy in human CD4+ T cells
- (2014) Margarita Dominguez-Villar et al. NATURE IMMUNOLOGY
- Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF
- (2014) J. P. Kolb et al. Science Signaling
- Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
- (2014) M. V. Dhodapkar et al. Science Translational Medicine
- Could Hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study
- (2014) Luca Topazio et al. BMC Urology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma
- (2014) Lorenzo Galluzzi et al. OncoImmunology
- Combined OX40 ligation plus CTLA-4 blockade
- (2014) Stefanie N Linch et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
- (2014) Linda C Sandin et al. OncoImmunology
- Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
- (2014) Lawrence J Thomas et al. OncoImmunology
- Trial watch: Dendritic cell-based anticancer therapy
- (2014) Norma Bloy et al. OncoImmunology
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
- (2013) Mark T. Orr et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
- (2013) Jean-Pascal Machiels et al. INVESTIGATIONAL NEW DRUGS
- Decoding cell death signals in liver inflammation
- (2013) Catherine Brenner et al. JOURNAL OF HEPATOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses
- (2013) Christopher B. Fox et al. VACCINE
- Aldara activates TLR7-independent immune defence
- (2013) Anne Walter et al. Nature Communications
- Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis
- (2013) Su Yin Lim et al. OncoImmunology
- Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
- (2013) Weiyi Peng et al. OncoImmunology
- Inhibiting the inhibitors
- (2013) Domenico Mavilio et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
- (2013) Lana E. Kandalaft et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- A TLR5 Agonist Enhances CD8+ T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease
- (2012) X. Ding et al. JOURNAL OF IMMUNOLOGY
- Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer
- (2012) Johannes Falke et al. JOURNAL OF UROLOGY
- Inflammasomes in carcinogenesis and anticancer immune responses
- (2012) Laurence Zitvogel et al. NATURE IMMUNOLOGY
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Mitochondria: master regulators of danger signalling
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structural Basis of TLR5-Flagellin Recognition and Signaling
- (2012) S.-i. Yoon et al. SCIENCE
- Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells
- (2012) Laura P. Schneider et al. VACCINE
- Sound efficacy of prophylactic HPV vaccination
- (2012) Matti Lehtinen et al. OncoImmunology
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs
- (2011) Harm C. Arentsen et al. BJU INTERNATIONAL
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
- (2011) Taro Kawai et al. IMMUNITY
- Reply to D. Herchenhorn et al
- (2011) Ezra E.W. Cohen JOURNAL OF CLINICAL ONCOLOGY
- Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
- (2011) Jitka Fučíková et al. Journal of Translational Medicine
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
- (2011) A. Carpentier et al. NEURO-ONCOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Targeting Toll-like receptors: emerging therapeutics?
- (2010) Elizabeth J. Hennessy et al. NATURE REVIEWS DRUG DISCOVERY
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
- (2010) S. Bertholet et al. Science Translational Medicine
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
- (2008) L. G. Burdelya et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now